Imagine eating a slice of chocolate cake not because you are hungry, but simply because it is there. Scientists call this hedonic feeding — eating for pleasure — and it is, frankly, very human. Now, a team at the University of Virginia has found something extraordinary: a new class of oral weight-loss pills appears to dial that pleasure-eating down, not by suppressing hunger, but by quietly reshaping a reward circuit buried deep inside the brain. The drugs in question are small-molecule GLP-1 receptor agonists, including orforglipron — already approved by the US Food and Drug Administration — and an experimental compound called danuglipron.

These are pill-based alternatives to the injectable medications that have made headlines worldwide, from Ozempic in clinics in São Paulo to Wegovy in GP surgeries in Stockholm. They are also cheaper to manufacture, which matters enormously for global access. But until now, almost nobody knew what they were actually doing inside the brain. The researchers used gene-editing techniques to give mice GLP-1 receptors that more closely resemble human ones.

When the animals received either drug, activity lit up in a region called the central amygdala — an area associated with craving and reward, not appetite. This pathway is entirely separate from the hypothalamus and hindbrain circuits that peptide drugs like semaglutide are already known to influence. In other words, these pills are pulling a different lever. That discovery opens a genuinely strange door.